Published in @HPBjournal, our 🌎 survey study on surgical management of pancreatic neck/body cancer with venous involvement 🔍: 📝 222 surgeons, 49 countries, 6 continents 📍 Heterogenity in surgical management strategies ⚠️ Need for prospective studies & guidelines

Congrats to Anouk Emmen and Thomas Stoop for excellent presentations in the #PresidentialSession #AHPBA2025 AHPBA Miami 🇺🇸: #DIPLOMA2 RCT🇪🇺 robot/lap 🤖 vs open Whipple and #PREOPANC4🇳🇱 implementation of surgery for locally advanced #PancreaticCancer on behalf of DPCG and

#AudioVisualAbstract : Nationwide Use and Outcome of Surgery for Locally Advanced #PancreaticCancer Following Induction Chemotherapy DPCG Thomas Stoop Marc Besselink rdcu.be/efZZh Dra. Jordana B Vilela Syed A. Ahmad

Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030. A recent Seminar discusses the need for novel therapies & future directions for research: hubs.li/Q03hN4Hj0

Congratulations on the phenomenal accomplishment of election to honorary fellowship American Surgical Annals of Surgery #ASA2025 Marc Besselink and all honorees

The impact of neoadjuvant therapy in left-sided resectable pancreatic cancer doi.org/10.1016/j.anno… Annals of Oncology 🔎multicenter study 👉Left-sided PDAC associated with worse OS 👉Neoadj. Tx in left-sided RPC associated with improved OS vs upfront surgery 🧐Side matters in GI

Nice study. Consistent with our ⁦SWOG Cancer Research Network⁩ 1505 Study. ⁦BJS⁩ ⁦Davendra Sohal⁩ Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma nature.com/articles/s4141…

Pancreatic cancer patients aren't all the same. 🧬 The PANAMA score identifies who really benefits from post-op chemo after FOLFIRINOX—saving some from unnecessary treatment. 🔗journals.lww.com/annalsofsurger…

#HoraEst Ammar Asrar Javed, MD PhD 🇺🇸 🇺🇸 #PhD ceremony Amsterdam UMC New York University PANC-PALS DPCG on #PancreaticCancer ⏩️Amazing work!! #Thesis hdl.handle.net/11245.1/d2bd0a… #PhD team: Chris Wolfgang Jine He Lois Daamen

Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study ⁦British Journal of Cancer⁩ nature.com/articles/s4141…

Distribution of the NCCN stages of #PancreaticCancer ? 16,412 pts (2017-2022) 🇳🇱 👉23% primary resectable 👉 8% borderline resectable 👉 11% locally advanced 👉 58% metastatic ⏩️ academic.oup.com/bjs/article/11…

HPB Journal Highlight ⭐️Ishida et al. Global survey shows big variation in how surgeons manage neck of pancreas cancers, especially with vascular involvement. Highlights the need for future studies & clearer guidelines! 🔗tinyurl.com/3myun89t 📊🌎 #PancreaticCancer #HPBSurgery

Published in BJS, unique nationwide 🇳🇱 data DPCG on National Comprehensive Cancer Network (NCCN) resectability staging of #PancreaticCancer at diagnosis: 🧷 23% PRPC 🧷 8% BRPC 🧷 11% LAPC 🧷 58% M1 … including stratification for tumour location. 👉 academic.oup.com/bjs/article/11…

Resectability stages of pancreatic cancer: nationwide reference ➡️ doi.org/10.1093/bjs/zn… This population-based study on the NCCN resectability stages of pancreatic adenocarcinoma indicates that the rate of LAPC was lower than reported in literature, whereas the rate of PRPC is

🎉 Congratulations to Hiroyuki Ishida on successfully completing a 2-year research fellowship CU Surgical Oncology ! Your dedication and hard work are truly inspiring. Marco Del Chiaro